Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | HPN | P05981 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140564 | 0.87 | ALDH1A1 (0.47) | CYP19A1LMNATSHRSCN2AHPN | |
| SCHEMBL2650646 | 0.82 | SCN2A (0.60) | LMNATSHRSCN2AHPNALDH1A1 | |
| SCHEMBL2240147 | 0.78 | SCN2A (0.56) | LMNASCN2AALDH1A1POLBMAPT | |
| SCHEMBL7826626 | 0.78 | MEN1 (0.48) | LMNASMN1; SMN2POLBMAPTMAPK1 | |
| SCHEMBL14861198 | 0.78 | SMN1; SMN2 (0.56) | LMNACYP3A4SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1387889 | 0.75 | CYP3A4 (0.44) | TSHRCYP3A4SMN1; SMN2ALDH1A1POLB | |
| Benzene SCHEMBL2793854 | 0.75 | CYP19A1 (0.72) | CYP19A1LMNATSHRVCAM1CYP3A4 | |
| SCHEMBL212845 | 0.75 | CYP19A1 (0.81) | CYP19A1LMNATSHRVCAM1CYP3A4 | |
| SCHEMBL7123299 | 0.74 | SCN2A (0.51) | LMNASCN2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL10383590 | 0.74 | ALDH1A1 (0.55) | CYP19A1LMNATSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391082-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2019-08-27 | — | — | US | disclosed |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-09-06 | — | — | US | disclosed |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-12-01 | — | — | US | disclosed |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-12-01 | — | — | US | disclosed |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-12-01 | — | — | US | disclosed |
| US-9447091-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2016-09-20 | — | — | US | disclosed |
| US-9447091-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2016-09-20 | — | — | US | disclosed |
| US-9447091-B2 | Protein kinase inhibitors | ORION CORPORATION (FI) | 2016-09-20 | — | — | US | disclosed |
| EP-2766354-B1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-05-18 | — | — | EP | disclosed |
| EP-2766354-B1 | PROTEIN KINASE INHIBITORS | ORION CORP (FI) | 2016-05-18 | — | — | EP | disclosed |
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2015-01-08 | — | — | US | disclosed |
| EP-2766354-A1 | PROTEIN KINASE INHIBITORS | Orion Corporation (FI) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013053983-A1 | PROTEIN KINASE INHIBITORS | ORION CORPORATION (FI) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013053983-A1 | PROTEIN KINASE INHIBITORS | ORION CORPORATION (FI) | 2013-04-18 | — | — | WO | disclosed |
| US-6919347-B2 | Bradykinin B1 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030229092-A1 | Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens | PHARMACOPEIA, INC. (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1196411-B1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1196411-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005783-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011548-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | CYP19A1 1690/4885LMNA 3373/4885TSHR 1818/4885 |
| US-20030229092-A1 | Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens | BDKRB1, BDKRB2, HRH2 | CYP19A1 2186/4885LMNA 4493/4885TSHR 2176/4885 |
| US-20160346254-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | CYP19A1 1690/4885LMNA 3373/4885TSHR 1818/4885 |
| US-20180250272-A1 | PROTEIN KINASE INHIBITORS | FGFR1, FGFR3, FGFR4 | CYP19A1 1586/4885LMNA 3470/4885TSHR 1845/4885 |
| US-10391082-B2 | Protein kinase inhibitors | FGFR1, FGFR3, FGFR4 | CYP19A1 1586/4885LMNA 3470/4885TSHR 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.